HSIC vs PHIO · P/E 24, rev $12.67B vs $10.4M cap
Henry Schein Inc (HSIC) versus Phio Pharmaceuticals Corp (PHIO) — a side-by-side from cached financials, not a winner call.
Henry Schein Inc (HSIC) is a medical distribution company listed on NASDAQ.
Phio Pharmaceuticals Corp (PHIO) is a biotechnology company listed on US.
Latest reported HSIC revenue for 2024-12-28 was $12.67B. Net income was $398.0M. Revenue was up 2.7% from 2023-12-30 to 2024-12-28. HSIC currently screens at market cap $9.11B and trailing P/E 24.2.
PHIO does not have a complete income-statement cache yet.
HSIC currently screens at market cap $9.11B and trailing P/E 24.2. PHIO currently screens at market cap $10.4M.
Not investment advice. Open the HSIC and PHIO stock pages for the full models.
Not investment advice.